To ascertain the patient profile and clinical conditions that characterise the indication for amyloid PET study.
To define the repercussions on immediate therapeutic planning/attitude of the result of the PET-amyloid study. The objective is to ascertain the extent to which the PET-amyloid study impacts the clinical diagnosis of suspicion established by the specialists who assess patients with cognitive impairment.
To generate of a database containing the various clinical and PET-amyloid-beta imaging features that can be used in the early diagnosis of Alzheimer's disease is underway.
